ICU — SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 19
- Website: https://www.seastarmedical.com
Latest SEC filings for ICU
- 10-Q — 2026-08-12
- 8-K — 2026-08-12
- 8-K — 2026-07-01
- 8-K/A — 2026-06-23
- 8-K — 2026-06-17
- 8-K — 2026-05-13
- 10-Q — 2026-05-13
- 424B3 — 2026-05-13
- 8-K — 2026-04-28
- 10-K — 2026-03-25
Latest ICU news
- — SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award (globenewswire.com)
- — FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition
- — SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds (globenewswire.com)
- — SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026 (globenewswire.com)
- — New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical's SCD Therapy for Acute Kidney Injury (AKI)
- — SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026 (globenewswire.com)
Educational tool only — not investment advice.